Showing results (51-60 of 93) with videos related to
Sort By:
Pageof 10
Research and Practice in Thrombosis and Haemostasis|August 14, 2025
Activated prothrombin complex concentrate in patients receiving emicizumab prophylaxis: from evidence to clinical practiceRobert F Sidonio, Guy Young, Carmen Escuriola Ettingshausen, et al.Polish Archives of Internal Medicine|July 5, 2020
Blood pressure profile, sympathetic nervous system activity, and subclinical target organ damage in patients with polycythemia veraKatarzyna Jóźwik-Plebanek, Piotr Dobrowolski, Jacek Lewandowski, et al.Polish Archives of Internal Medicine|April 13, 2017
Management of bleeding or urgent interventions in patients treated with direct oral anticoagulants: 2017 recommendations for PolandPiotr Pruszczyk, Anna Tomaszuk-Kazberuk, Agnieszka Słowik, et al.Blood Advances|July 17, 2026
Denecimig (Mim8) prophylaxis once-every-2-weeks for hemophilia A with or without inhibitors - 26-week results from FRONTIERTadashi Matsushita, Atanas Banchev, Julien Bovet, et al.Haematologica|October 2, 2025
Real-world safety and efficacy of rADAMTS13 prophylaxis in congenital thrombotic thrombocytopenic purpura: experience from Polish patients previously treated with fresh frozen plasmaJerzy Windyga, Joanna Zdziarska, Magdalena Górska-Kosicka, et al.British Journal of Haematology|September 12, 2014
Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding ratesJerry Powell, Amy Shapiro, Margaret Ragni, et al.Journal of Thrombosis and Haemostasis : JTH|September 17, 2023
Evaluation of collagen turnover biomarkers as an objective measure for efficacy of treatment with rurioctocog alfa pegol in patients with hemophilia A: a secondary analysis of a randomized controlled trialTina Manon-Jensen, Srilatha Tangada, Cecilie Bager, et al.Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|May 11, 2010
Polymorphisms in the factor VII gene and ischemic stroke in young adultsStanislaw Lopaciuk, Jerzy Windyga, Cezary W Watala, et al.Journal of Thrombosis and Haemostasis : JTH|April 4, 2012
Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trialErich V de Paula, Kaan Kavakli, Johnny Mahlangu, et al.Blood|August 5, 2015
Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand diseaseJoan C Gill, Giancarlo Castaman, Jerzy Windyga, et al.Pageof 10